Manato Ohara, diagnosed with type 1 diabetes
Kanagawa, Japan

novo nordisk – a focused healthcare company

US approval of Ozempic®

6 December 2017

Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company's Annual Report 2016 and Form 20-F, which are both filed with the SEC in February 2017 in continuation of the publication of the Annual Report 2016, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

- Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto
- Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures
- Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
- Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recall, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.

Please also refer to the overview of risk factors in 'Risk Management' on pp 40-43 of the Annual Report 2016.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise.

Important drug information

- Victoza® (liraglutide 1.2 mg & 1.8 mg) is approved for the management of type 2 diabetes only
- Saxenda® (liraglutide 3 mg) is approved in the US and EU for the treatment of obesity only

US Food and Drug Administration approves Ozempic®

Regulatory review timeline of Ozempic®



Competitive US label for Ozempic®

Ozempic® approved in the US and launch is planned for Q1 2018

Profile	• Ozempic® is indicated as an adjunct to diet and exercise to **improve glycaemic control** in adults with type 2 diabetes • Ozempic® is approved for use in two therapeutic dosages, 0.5 mg and 1 mg
Efficacy	• Statistically significant **reduction in HbA_{1c}** compared with placebo, sitagliptin, exenatide extended-release and insulin glargine U100 • Statistically significant **reduction in body weight** confirmed in all trials against all comparators
Safety	• Ozempic® demonstrated a **safe and well-tolerated profile** across the SUSTAIN programme • In SUSTAIN 6, there were 108 MACE events with Ozempic® compared to 146 events with placebo, equivalent to an event rate of **6.6% with Ozempic® and 8.9% with placebo**
Convenience	• To be launched in the **Ozempic® Pen**, the latest generation of Novo Nordisk prefilled devices • **Once-weekly** subcutaneous injections

MACE: Major adverse cardiovascular event

Investor contact information

Share information

Novo Nordisk's B shares are listed on the stock exchange in Copenhagen under the symbol 'NOVO B'. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For further company information, visit Novo Nordisk on the internet at: novonordisk.com

Upcoming events

01 Feb 2018	Financial statement for 2017
22 Mar 2018	Annual General Meeting
02 May 2018	Financial statement for the first three months of 2018
08 Aug 2018	Financial statement for the first six months of 2018
01 Nov 2018	Financial statement for the first nine months of 2018

Investor Relations contacts

Novo Nordisk A/S
Investor Relations
Novo Allé, DK-2880 Bagsværd

Peter Hugreffe Ankersen	+45 3075 9085	phak@novonordisk.com
Hanna Ögren	+45 3079 8519	haoe@novonordisk.com
Anders Mikkelsen	+45 3079 4461	armk@novonordisk.com
Christina Kjær	+45 3079 3009	cnje@novonordisk.com

In North America:

Kasper Veje	+1 609 235 8567	kpvj@novonordisk.com